Coya Therapeutics, Inc. (COYA)

NASDAQ: COYA · USD

$4.06

-0.07 (-1.6%)· Recorded snapshot

Market cap	95.1M
Revenue (ttm)	8M
Net income (ttm)	-21.7M
EPS (ttm)	-$1.09
Shares out	23.5M
Volume	143,588
Beta	0.58

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 8M
Net income (ttm): -21.7M
EPS (ttm): -$1.09
Market cap: 95.1M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Conserver

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 13.4P50 20.2P75 35.7

Trailing P/En/a

P25 15.4P50 25.8P75 43.5

ROE-60.5

P25 -113.8P50 -46.5P75 -0.9

ROIC-36.4

P25 -68.5P50 -27.1P75 1.8

Benchmarks · 1M

All COYA indicators

Market & fundamental data

Available fields

192

Groups with data

Currency

USD

Showing 192 of 192 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001835022
Company name	Coya Therapeutics, Inc.
Country	United States
Country code	US
CUSIP number	22407B108
Earnings date	2026-11-11
Earnings time	bmo
Employees	8
Employees change	2
Employees growth	33.33%
Enterprise value	$51.9M
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	2020
Industry	Biotechnology
IPO date	2022-12-29
Is primary listing	Yes
Is SPAC	No
ISIN number	US22407B1089
Last 10-K release date	2026-03-16
Last earnings date	2026-08-11
Last refreshed	2026-10-28
Last stock split type	Never
Market cap	$95.1M
Market cap category	Micro-Cap
Next earnings date	2026-11-11
Options	Yes
Price	$4.06
Price currency	USD
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-28
Symbol	COYA
U.S. state	Texas
Website	https://www.coyatherapeutics.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-26.86%
EV/Sales	6.67x
FCF / EV yield	-29.41%
FCF yield	-16.27%
Forward EV/Sales	13.09x
Forward P/S	23.67x
P/B ratio	2.23x
P/S ratio	12.05x
Price / tangible book value	2.23x
Sector forward P/E	23.56x
Sector P/E	50.13x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	-260%
EBITDA margin	-259.76%
Gross margin	-111.8%
Operating margin	-260%
Pretax margin	-270.19%
Profit margin	-270.22%
Profit per employee	$-2.7M
Revenue per employee	$1M
ROA	-32.27%
ROA (5Y)	-40.71%
ROCE	-47.61%
ROE	-60.54%
ROIC	-36.41%
SBC / revenue	66.27%
Tax / revenue	0.04%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth quarters	2
EPS growth years	0
Net income growth years	0
Revenue growth	1,793.76%
Revenue growth (Q)	48.97%
Revenue growth (QoQ)	-2.95%
Revenue growth quarters	1
Revenue growth years	1

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Depreciation and amortization	$19,295
EBIT	$-20.8M
EBITDA	$-20.8M
EPS	$-1.09
FCF per share	$-0.67
Financing cash flow	$31.2M
Free cash flow	$-15.7M
Free cash flow minus SBC	$-21M
Gross profit	$-9M
Income taxes	$3,089
Investing cash flow	$-2.1M
Net cash flow	$13.4M
Net income	$-21.7M
Operating cash flow minus SBC	$-21M
Operating income	$-20.8M
Revenue	$8M
Stock-based compensation	$5.3M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	13.8
Book value per share	$1.84
Debt / equity	0
Long-term assets	$250,341
Long-term liabilities	$519,636
Net cash (debt)	$43.2M
Net cash / market cap	44.68%
Net cash growth	45.11%
Net debt / equity	-1
Piotroski F-Score	4
Property, plant and equipment	$5,614
Shareholders' equity	$43.3M
Tangible book value	$43.3M
Tangible book value per share	$1.84
Total assets	$47.3M
Total cash	$43.2M
Total debt	$0
Total liabilities	$4M
WACC	7.44%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.2
Current assets	$47.1M
Current liabilities	$3.5M
Current ratio	13.4
Net working capital	$364,304
Quick ratio	12.29
Working capital	$43.5M
Working capital turnover	0.22

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-22.38%
Dividend yield	0%
Shareholder yield	-22.38%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	$4.65
1D price change	-1.58%
1M price change	-20.18%
1M total return	-20.18%
1W price change	-2.05%
1W total return	-2.05%
1Y price change	-37.33%
1Y return CAGR	-37.35%
1Y total return	-37.33%
20-day SMA	$4.45
200-day SMA	$4.65
3M price change	-4.92%
3M total return	-4.92%
3Y price change	-12.8%
3Y return CAGR	-4.46%
3Y total return	-12.8%
50-day SMA	$4.66
50-day SMA vs 200-day SMA	50over200
52-week high	$6.77
52-week high date	2025-10-28
52-week low	$3.71
52-week low date	2026-03-30
6M price change	-7.84%
6M total return	-7.84%
All-time high	$10.69
All-time high date	2024-03-18
All-time low	$3.21
All-time low date	2023-08-18
Average true range (ATR)	$0.26
Average volume	131.6K
Beta (1Y)	1.81
Beta (2Y)	1.47
Beta (5Y)	0.58
Change from 52-week high	-40.14%
Change from 52-week low	9.3%
Change from all-time high	-62.07%
Change from all-time low	26.32%
Change from open	-1.1%
Day's gap	-0.49%
Dollar volume	$582,249
High price	$4.13
Low price	$4.06
Monthly RSI	44.73
Open price	$4.10
Position in 52-week range	0%
Previous close	$4.12
Price vs 150-day SMA	-12.72%
Price vs 20-day SMA	-8.77%
Price vs 200-day SMA	-12.81%
Price vs 50-day SMA	-12.91%
Relative volume	1.12
Return from IPO open	-13.26%
Return from IPO price	-17.6%
RSI	36.7
Sharpe ratio	-0.56
Sharpe ratio (3Y)	0.21
Sortino ratio	-0.7
Sortino ratio (3Y)	0.4
Volume	143.6K
Weekly RSI	42.5
YTD price change	-30.09%
YTD total return	-30.09%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	17.5M
Float percentage	74.79%
Shares change (QoQ)	3.59%
Shares change (YoY)	22.38%
Shares held by insiders	5.57%
Shares held by institutions	23.32%
Shares outstanding	23.5M
Short % of float	7.15%
Short % of shares	5.35%
Short ratio	8.5 days

Deeper analysis on COYA

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this COYA report

Is a complete COYA research report available?

No complete published report is available for Coya Therapeutics, Inc. (COYA) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Coya Therapeutics, Inc. (COYA)

Price

Financial snapshot

Fair-value bridge

Latest news · COYA

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All COYA indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on COYA

Frequently asked questions